MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
warrants and new...
$7,243,143
Proceeds from issuance of
common stock,...
$5,788,380
Cash provided by
financing activities
$13,031,523
Increase (decrease) in
cash and cash...
-$10,092,574
Canceled cashflow
$13,031,523
Stock-based compensation
$2,263,704
Depreciation and
amortization
$213,597
Prepaid expenses and
other assets
-$119,233
Change in operating
lease right-of-use...
$76,202
Cash used in
operating activities
-$23,118,217
Canceled cashflow
$2,672,736
Cash used in
investing activities
-$5,880
Net loss
-$21,791,037
Accounts payable and
accrued liabilities
-$3,161,792
Change in fair value of
warrants
-$753,707
Lease liability
-$84,417
Purchases of property,
plant & equipment
$5,880
Back
Back
Cash Flow
source: myfinsight.com
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)